TY - JOUR T1 - Locus coeruleus pathology in progressive supranuclear palsy, and its relation to disease severity JF - medRxiv DO - 10.1101/2020.01.13.20016360 SP - 2020.01.13.20016360 AU - Sanne Simone Kaalund AU - Luca Passamonti AU - Kieren SJ Allinson AU - Alexander G Murley AU - Trevor W Robbins AU - Maria Grazia Spillantini AU - James B Rowe Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/01/16/2020.01.13.20016360.abstract N2 - The locus coeruleus is the major source of noradrenaline to the brain and contributes to a wide range of physiological and cognitive functions including arousal, attention, autonomic control, and adaptive behaviour. Neurodegeneration and pathological aggregation of tau protein in the locus coeruleus are early features of progressive supranuclear palsy (PSP). This pathology is proposed to contribute to the clinical expression of disease, including the PSP Richardson’s syndrome. We test the hypothesis that tau pathology and neuronal loss are associated with clinical heterogeneity and severity in PSP.We used immunohistochemistry in post mortem tissues from 31 patients with a clinical diagnosis of PSP (22 with Richardson’s syndrome) and 6 control cases. We quantified the presence of hyperphosphorylated tau, the number of pigmented cells indicative of noradrenergic neurons, and the percentage of pigmented neurons with tau-positive inclusions. Ante mortem assessment of clinical severity using the PSP rating scale was available within 1.8 (±0.9) years for 23 patients.We found an average 49% reduction of pigmented neurons in PSP patients relative to controls. The loss of pigmented neurons correlated with disease severity, even after adjusting for disease duration and the interval between clinical assessment and death. The degree of neuronal loss was associated with tau-positive inclusions, with an average of 44% of pigmented neurons displaying tau-inclusions.Degeneration and tau pathology in the locus coeruleus are related to clinical heterogeneity of PSP. The noradrenergic deficit in the locus coeruleus is a candidate target for pharmacological treatment. Recent developments in ultra-high field magnetic resonance imaging to quantify in vivo structural integrity of the locus coeruleus may provide biomarkers for noradrenergic experimental medicines studies in PSP.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialit is not a clinical trialFunding StatementThis work was funded by Lundbeck Fonden R232-2016-2333, and R265-2017-3722; Wellcome Trust (103838); Medical Research Council (MC_U105597119 & MC_UU_00005/12 & SUAG004/051 RG91365), the Holt fellowship, NIHR Cambridge Biomedical Research Centre and Cambridge Brain Bank, and the Cambridge Centre for Parkinson plus. The Cambridge Brain Bank is supported by the NIHR Cambridge Biomedical Research CentreAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used are available from the corresponding author on reasonable request.ANOVAanalysis of varianceACE-Rrevised Addenbrooke’s cognitive examinationCBI-Rrevised Cambridge Behavioural InventoryCBScorticobasal syndromeMRImagnetic resonance imagingMMSEMini Mental State ExaminationNINDSNational Institute of Neurological Disorders and StrokePSPprogressive supranuclear palsyPSPRSPSP rating scalePSP-SLpossible PSP with predominant speech/language disorder ER -